Dr. Ryan Moy
Claim this profileNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
Studies Cancer
Studies Colorectal Cancer
6 reported clinical trials
14 drugs studied
Area of expertise
1Cancer
Stage IV
Mismatch Repair Deficiency positive
Stage III
2Colorectal Cancer
Stage IV
Mismatch Repair Deficiency positive
Stage III
Affiliated Hospitals
Clinical Trials Ryan Moy is currently running
BMS-986340 + Nivolumab/Docetaxel
for Cancer
This trial tests a new drug, BMS-986340, alone and with other cancer treatments (nivolumab and docetaxel) in patients with advanced solid tumors. The goal is to find out if it is safe and effective in treating these cancers.
Recruiting1 award Phase 1 & 26 criteria
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
More about Ryan Moy
Clinical Trial Related3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Ryan Moy has experience with
- 9-ING-41
- BMS-936558-01
- BMS-986340
- Docetaxel
- BAY 1895344
- Fluorouracil
Breakdown of trials Ryan Moy has run
Cancer
Colorectal Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Neoplasms
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ryan Moy specialize in?
Ryan Moy focuses on Cancer and Colorectal Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Mismatch Repair Deficiency positive.
Is Ryan Moy currently recruiting for clinical trials?
Yes, Ryan Moy is currently recruiting for 4 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Ryan Moy has studied deeply?
Yes, Ryan Moy has studied treatments such as 9-ING-41, BMS-936558-01, BMS-986340.
What is the best way to schedule an appointment with Ryan Moy?
Apply for one of the trials that Ryan Moy is conducting.
What is the office address of Ryan Moy?
The office of Ryan Moy is located at: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York 10032 United States. This is the address for their practice at the NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.